AJCN EB Program 2010
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stettler, N.
Right arrow Articles by Zemel, B. S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stettler, N.
Right arrow Articles by Zemel, B. S
Agricola
Right arrow Articles by Stettler, N.
Right arrow Articles by Zemel, B. S
American Journal of Clinical Nutrition, Vol. 72, No. 2, 407-413, August 2000
© 2000 American Society for Clinical Nutrition

Original Research Communications

Prospective evaluation of growth, nutritional status, and body composition in children with cystic fibrosis1,2,3

Nicolas Stettler, Deborah A Kawchak, Lisa L Boyle, Kathleen J Propert, Thomas F Scanlin, Virginia A Stallings and Babette S Zemel

1 From the Division of Gastroenterology and Nutrition, The Cystic Fibrosis Center, The Children's Hospital of Philadelphia; the Department of Pediatrics and Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia; and the Wisconsin School of Medicine, Madison.

2 Supported by The Cystic Fibrosis Foundation, the Nutrition Center, and the General Clinical Research Center (RR-00240) of The Children's Hospital of Philadelphia.

3 Address reprint requests to BS Zemel, Division of Gastroenterology and Nutrition, The Children's Hospital of Philadelphia, 34th Street and Civic Center Boulevard, Philadelphia, PA 19104-4399. E-mail: zemel{at}email.chop.edu.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Background: Several cross-sectional studies have shown improvement in the growth of children with cystic fibrosis (CF) because of increased awareness of and more comprehensive care of their special nutritional needs. However, longitudinal data on the nutritional status of these children are rare.

Objective: The objective was to compare changes in growth, body composition, and nutritional status between children with and without CF.

Design: This was a prospective 3-y cohort study of 25 children aged 5–10 y with CF, mild pulmonary disease, and pancreatic insufficiency and of 26 healthy control children. Three methods were used to assess body composition: measurements of skinfold thickness, total body water by deuterium oxide, and total-body electrical conductivity. Growth and body-composition changes over time were analyzed by a longitudinal mixed-effects model.

Results: Over the 3 y of the study, the statural growth of the boys with CF was slower than that of the control subjects (P = 0.004). The same divergence over time between the boys with and without CF was observed for fat-free mass assessed by skinfold-thickness measurements and total body water (P = 0.008 and 0.02, respectively) and for fat mass assessed by skinfold-thickness measurements and total-body electrical conductivity (P = 0.009 and 0.001, respectively). The differences in the pattern of changes in growth and body composition were less striking for girls.

Conclusions: Despite comprehensive care, the growth of boys with CF was impaired on the basis of height, fat-free mass, and fat mass, when observed longitudinally. Caution should be used when interpreting cross-sectional measurements because they often do not detect suboptimal growth.

Key Words: Body composition • children • cystic fibrosis • deuterium oxide • genotype • growth • longitudinal studies • mixed-effects model • nutritional status • respiratory function tests • total-body electrical conductivity • total body water


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Suboptimal growth is frequent in children with cystic fibrosis (CF) and is associated with increased morbidity and mortality (1–6). In the past few decades, the growth of these children has improved because of increased awareness of and more comprehensive care of their special nutritional needs (4, 7). Many children with CF have achieved growth above the third percentile and appear to have normal growth when weight and height are measured cross-sectionally (3). These apparent achievements might, however, be misleading in evaluations of individual children over time. Even when final height is above the third percentile, there still may be a growth deficit relative to the individual genetic potential for height. Furthermore, weight is a composite value of the 2 major body components: fat-free mass (FFM) and fat mass (FM). Therefore, the separate observation of changes in these 2 body compartments may provide more information on the growth patterns of children with CF.

To evaluate growth more fully, investigators have recommended the use of several methods of body-composition assessment (8, 9). Furthermore, prospective examinations of the changes in body composition provide insight into the mechanisms that underlie body-composition deficits in CF. In the current study, changes in FFM and FM were evaluated prospectively by using 3 different methods. At the initiation of this longitudinal study of preadolescent children, FFM and FM were similar by design in both groups (10).

The purpose of this study was to characterize over 3 y the longitudinal changes in body composition and growth of clinically stable prepubertal children with CF, mild pulmonary disease, and pancreatic insufficiency, and to compare these changes with those observed in healthy control children. The influence of age and sex on these changes was also examined.


   SUBJECTS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Subjects
Twenty-five subjects (12 boys and 13 girls) aged 5–10 y with CF were recruited from the Cystic Fibrosis Center at The Children's Hospital of Philadelphia. The diagnosis of CF was based on clinical signs and on sodium and chloride values >60 mmol/L as measured in duplicate quantitative pilocarpine iontophoresis sweat tests. At baseline, all subjects with CF were prepubertal and pancreatic insufficient, with mild pulmonary disease, ie, a forced expiratory volume at 1 s (FEV1) >60% as measured by standard methods. All subjects had adequate growth status on the basis of a screening definition of height and weight above the third percentile. The subjects had no other chronic disorders and were not taking medications known to affect growth or nutritional status. Twenty-six healthy prepubertal children (15 boys and 11 girls), similar to the children with CF in age, sex, and weight, were recruited from hospital and community sources. Subjects were evaluated annually 4 times over 3 y while in their usual state of good health. Genomic DNA was analyzed as described previously (11). Subjects with CF were classified as those homozygous for the {Delta}F508 allele, those heterozygous for the {Delta}F508 allele, and those with non-{Delta}F508 alleles. Genotypes were not obtained for control subjects.

The protocol was approved by the Institutional Review Board at The Children's Hospital of Philadelphia. Informed, written consent was obtained from the parents of the children. All studies were conducted during an 18-h overnight admission to the General Clinical Research Center and all measurements were made at the Nutrition and Growth Laboratory.

Anthropometric and body-composition evaluations
Weight, height, midupper arm circumference, and skinfold thickness (SFT) at the triceps, biceps, subscapular, and suprailiac sites were measured in triplicate by using standard methods (12). One well-trained anthropometrist conducted the evaluation in the first year; a second well-trained anthropometrist conducted the evaluation in subsequent years. Pubertal development was scored according to Tanner (13). The average of the genital and pubic hair development scores was used in the analysis.

Upper arm muscle area was calculated from anthropometric measures (14). FFM and FM were measured by using several methods of body-composition assessment because no single method is recognized as optimal for children with CF. First, FFM and FM were computed from SFT measurements at 4 sites with the use of age- and sex-appropriate prediction equations (15, 16).

Total body water (TBW) was measured by the deuterium oxide (2H2O) dilution method (17). A baseline urine sample was obtained and then 2H2O was administered orally 1.5 h after consumption of a standardized evening meal. The dose (0.14 g 2H2O/kg estimated total body water) was of 99.8 or 99.9 atom percent deuterium (Aldrich Chemical, Milwaukee). Urine was collected overnight and pooled with the first urine sample of the morning. The volume and deuterium concentration of the pooled sample were used to estimate isotope losses during the equilibration period. The second morning urine sample was collected and analyzed to calculate TBW. Urinary 2H2O isotopic abundance was measured by isotope ratio mass spectroscopy (18) (Nuclide 6-60; State College, PA) by 1 of 2 laboratories (Global Geochemistry Corporation, Canoga Park, CA, or Metabolic Solutions, Merrimack, NH). Agreement between laboratories was established by analyzing duplicate samples. FFM and FM were derived from TBW by using a hydration factor of 75.3% for prepubertal children (19).

Body composition was also determined by total-body electrical conductivity (TOBEC) (HA-2; EmScan, Springfield, IL). The TOBEC instrument contains a low-energy electromagnetic field through which the subject moves on a gantry table. Changes in the energy field are caused by the conductivity of the water and electrolytes in the FFM (8, 20, 21). These measured changes are used to determine FFM and FM on the basis of age-appropriate calibration equations.

Statistical analysis
Heights and weights were compared with National Center for Health Statistics reference standards (22), and z scores (SD scores) were calculated with the ANTHROPOMETRIC SOFTWARE PROGRAM (version 3.1, 1988; Centers for Disease Control and Prevention, Atlanta). Means and CIs for growth and body-composition measures were calculated by group and sex at each time point and plotted to examine time trends. Baseline group comparisons were made by using a two-sample t test. Comparisons of the changes between groups from the beginning to the end of the study were made by using a two-sample t test when the distribution was normal and by using Wilcoxon's rank-sum test when the distribution was not normal.

Comparisons of body-composition methods for individual measurements were described by using a Spearman's rho correlation coefficient and by calculating the mean differences between methods. All reported P values are two-tailed and values <=0.05 were considered significant. The longitudinal mixed-effects model of Laird and Ware (23) was used to examine longitudinal trends. This approach allows analysis of the linear association between repeated measurements of an outcome variable and both time and other explanatory variables such as CF group and control group. The data from all subjects were included in the analysis, even when some subjects did not have a complete set of measurements. Therefore, this analysis was more likely to detect differences undetected by simple comparison of differences between groups. A random effect was included in each model to account for within-subject random variability. The models examined changes over time in growth and body composition, and whether patterns of change were different between the CF and control groups. Parameter estimates, as in regression analysis, indicate the contribution of the independent variable to the model. For example, the parameter estimate for the time variable estimates the rate of change in the dependent variable over time. Boys and girls were analyzed separately because of the expected sex differences in growth and body composition. Statistical evaluation was conducted by using STATA 5.0 (STATA Corp, College Station, TX).


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Fourteen of the 25 children with CF had the {Delta}F508/{Delta}F508 genotype, 7 had the {Delta}F508/other genotype, and 4 had the other/other genotype. Boys and girls were evenly distributed in the genotype groups. There was one child of African ancestry in the CF and the control groups; all other children were of European ancestry.

Of 204 potential subject visits over 3 y (4 annual visits for the 51 subjects), subjects completed a total of 185 visits (91%). Anthropometric evaluations of growth were completed at each visit. However, because of occasional equipment or protocol failure, not all methods were used for each subject at each study visit. There were 182 sets of SFT measurements, 181 TBW measurements, and 173 TOBEC measurements of body composition. One subject with CF and one control subject were seen only once. The sample sizes for each measurement at each time point are shown in Table 1Go. TOBEC was not assessed in 9 of 25 CF subjects and in none of the 26 control subjects at the beginning of the study (baseline) because this method was not available at the time. Sex distribution, age, height, and height-for-age z (HAZ) score were similar between the 9 children in whom TOBEC was not measured and the 16 children in whom TOBEC was measured. The former group, however, was on average heavier (26.4 compared with 22.5 kg; P = 0.03) and had a higher weight-for-age z (WAZ) score at baseline (0.19 compared with –0.60; P = 0.02) than did the latter group. Because these differences could introduce a bias in the longitudinal analysis, an alternate model was constructed that did not include the TOBEC measurements of the children with CF in the first year. The results were the same, with minor exceptions as discussed below. The consistency between the results of the different body-composition methods for each individual FFM measurement was as follows (number of observations, Spearman's rho, percentage mean difference): TBW versus TOBEC (169, 0.97, 4.0%), TBW versus SFT (178, 0.95, 0.4%), and TOBEC versus SFT (170, 0.97, 4.8%). For FM, the values were as follows: TBW versus TOBEC (169, 0.81, 39.3%), TBW versus SFT (178, 0.67, 21.0%), and TOBEC versus SFT (170, 0.83, 18.0%).


View this table:
[in this window]
[in a new window]
  		TABLE 1.. Growth and pulmonary function in children with cystic fibrosis (CF) and in healthy control children1
 
The mean age, weight, and height of the subjects and the FEV1 of the children with CF at each follow-up time point are presented in Table 1Go. At baseline (time 0), age, weight, and height were not significantly different between CF and control subjects. WAZ and HAZ scores are presented over time for each group in Figure 1Go. At baseline, WAZ scores were not significantly different between CF and control subjects. HAZ scores were significantly lower in boys with CF than in boys without CF (P = 0.01).



View larger version (19K):
[in this window]
[in a new window]
  		FIGURE 1. . Mean (±SD) changes in weight-for-age (WAZ) and height-for-age (HAZ) z scores in children with cystic fibrosis (•; n = 25) and in healthy control children ({circ}; n = 26) over 3 y.

 
Changes in absolute values of weight, height, and body composition from the beginning to the end of the study are presented in Table 2Go. Changes over time in WAZ and HAZ scores were also evaluated by using a longitudinal mixed-effects model with initial age, time, group, and a time-by-group interaction as independent variables. Although WAZ scores appeared to decrease over time in boys (P = 0.002) and girls (P = 0.04), there were no significant differences between the CF and the control groups. In contrast, there was a significant group-by-time interaction for HAZ scores in boys (P = 0.004) and girls (P = 0.04). This interaction term describes the divergence over time between the CF and the control groups. In general, HAZ scores decreased over time in children with CF, whereas HAZ scores remained essentially constant in control subjects.


View this table:
[in this window]
[in a new window]
  		TABLE 2.. Changes in weight, height, fat-free mass (FFM), fat mass (FM), and percentage fat from the beginning to the end of the study1
 
At baseline, FFM was not significantly different between CF and control subjects, regardless of the body-composition-assessment method used. The changes in FFM determined by TBW, TOBEC, and SFT are presented in Table 2Go and Figure 2Go. Analysis of the longitudinal data for boys showed that initial age, time, and time-by-group interaction contributed significantly to changes in FFM determined by TBW (P < 0.001, P < 0.001, and P = 0.02, respectively) and SFT (P < 0.001, P < 0.001, and P = 0.008, respectively), but only initial age (P < 0.001) and time (P < 0.001) contributed significantly to the model using TOBEC for FFM assessment. In girls, only initial age and time contributed to the model in all 3 methods of FFM assessment (all P values < 0.001). However, when the alternative statistical model for TOBEC measurement was used, which did not include children with CF at baseline, the time-by-group interaction term was significant in girls (P = 0.043). Upper arm muscle area was not significantly different between CF and control subjects at baseline. Longitudinal changes in upper arm muscle area were significantly explained by time in boys and by time and initial age in girls, but changes in upper arm muscle area were not significantly different between the CF and control groups.



View larger version (23K):
[in this window]
[in a new window]
  		FIGURE 2. . Mean (±SD) changes in fat-free mass (FFM) determined by total body water (TBW), total-body electrical conductivity (TOBEC), and skinfold thickness (SFT) in children with cystic fibrosis (•; n = 25) and in healthy control children ({circ}; n = 26) over 3 y.

 
Changes in FM were also analyzed to evaluate energy stores. At baseline, FM determined by TBW was significantly lower in boys with CF than in control boys (P = 0.004; Figure 3Go). There were no significant differences in girls. Similar results were observed in boys when TOBEC (P = 0.01) and SFT (P = 0.04) were used. In boys, the time-by-group interaction term predicted changes in FM determined by TOBEC (P = 0.001) and SFT (P = 0.009) only. In girls, the time-by-group interaction term contributed negatively to the model of FM changes when determined by TBW (P = 0.05), indicating that girls with CF gained more fat over time than did the control girls.



View larger version (22K):
[in this window]
[in a new window]
  		FIGURE 3. . Mean (±SD) changes in fat mass (FM) determined by total body water (TBW), total-body electrical conductivity (TOBEC), and skinfold thickness (SFT) in children with cystic fibrosis (•; n = 25) and in healthy control children ({circ}; n = 26) over 3 y.

 
Because puberty began in 9 of the 24 girls during the study, a secondary analysis was conducted in girls to introduce any detectable pubertal changes (Tanner stage 2) as a dichotomous variable to fit a model, assuming a change point at initiation of puberty. This variable contributed significantly to every model (all P values < 0.01), but the results reported above remained essentially the same with only a few exceptions. After inclusion of pubertal changes in the model, initial age contributed to the model of WAZ scores (P = 0.012), the group-by-time interaction term was no longer significant in the model of HAZ scores, the group-by-time interaction term was no longer significant in the model of FM by TBW, and initial age was no longer significant in the model of FM by TOBEC. Because only 2 of the 27 boys showed detectable signs of pubertal changes, no similar analysis was conducted in boys. Because of the observed differences in results between the sexes, a separate secondary analysis also was performed with use of a sex-by-time interaction term to compare changes in WAZ scores, HAZ scores, FFM, and FM between boys and girls with CF. Only changes in FM were significantly different between the sexes, with girls having more FM than boys, as determined by TBW (P = 0.02), TOBEC (P = 0.004), and SFT (P < 0.001). The different CF genotypes did not contribute significantly to any of the models for change in weight, height, FFM, and FM for this group of children with CF and pancreatic insufficiency.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
The body-mass compartments of the children with CF, mild pulmonary symptoms, and pancreatic insufficiency did not change as did those of the control subjects when observed prospectively over several years. Previous cross-sectional studies showed that adults and children with CF have deficits in both FFM and FM as early as 5 wk of age (24–28). Furthermore, in a prospective study, Farrell et al (29) showed higher growth rates on the basis of weight and height assessments in children in whom CF was diagnosed at birth than in children in whom CF was diagnosed later in life (0–7 y). Similar results were observed in infants and young children (25, 30). However, prospective changes in the body composition of older children with CF have not been documented. Body-composition assessment in children with CF may be complicated by the characteristics of the disease (31, 32). Hydrodensitometry, usually referred to as the optimal method for measuring body composition in healthy adult subjects, may be unreliable in adults and children with CF (8, 33). Except for hydrodensitometry, different methods of body-composition assessment have been shown to correlate well with each other, but absolute FFM and FM values may vary between methods. The present study showed consistency between methods for FFM, but not for assessments of FM in individuals. Therefore, as in the present study, the use of several methods of body-composition assessment in research settings may be more reliable for describing the longitudinal changes in body composition of children with CF (9).

This study was designed to assess longitudinal changes in growth, body composition, energy expenditure, and pulmonary function in children with adequate growth status and mild pulmonary symptoms of CF (34). Control subjects were therefore selected at baseline to be similar in age and weight to the children with CF, explaining the initial similarities between the 2 groups, except for HAZ scores in boys. The decrease in WAZ scores with time in boys and girls in both groups may have resulted from impairments in nutritional status in the children with CF, but was not easily explained in the control children. In boys, greater differences in HAZ scores over time were observed between the CF and control groups. This finding emphasizes the fact that even when cross-sectional anthropometric indexes are comparable between CF and control groups, CF subjects may suffer a delay in statural growth, a phenomenon best observed in longitudinal studies.

Similarly, by design, total weight and FFM were comparable at baseline between the 2 groups. However, boys with CF gained less FFM than did control boys over the 3 y of the study. The present study suggests that the girls with CF and the control girls had similar increases in FFM during the entire study period. When the TOBEC determinations over the first year for girls with CF were not included in the analysis, this interaction term became significantly negative, suggesting that subjects with CF gained more FFM than did control girls. This result should, however, be interpreted with caution. The growth deficiency in FFM observed in boys with CF might reflect the energy deficit experienced by these children because no dietary protein deficiency was observed (35).

The dietary data at the initiation of this study suggest that the children with CF had normal growth with energy intakes that were higher than those of the control subjects, yet lower than the recommended intakes for children with CF (35). The present longitudinal study showed that dietary intakes at this level were likely insufficient to ensure normal growth over the 4 y of follow-up. Unlike FFM, upper arm muscle area did not differ significantly between the CF and control groups. This difference emphasizes the limitation of change in upper arm muscle area as an indicator of FFM changes. In an evaluation of fat stores, and thus of cumulative energy stores over the 3 y of the study, boys with CF gained significantly less FM than did control boys and girls with CF. This difference is explained by the relative energy deficit in boys with CF. The sex difference in FM change was unexpected because boys usually have a better survival rate than do girls. This result suggests a possible interaction between sex, growth, and survival that should be investigated. An alternative explanation is that sex differences in FM are unrelated to survival.

Although the absolute differences between the children with CF and the control children were small, they were thought to be clinically significant for the following reasons. First, follow-up was limited to 3 y and the observed growth deficits likely were cumulative over childhood. Second, by design, the control group was selected to be of similar weight to the children with CF at baseline. Therefore, the control group might have been genetically smaller than the general population, thus underestimating the growth deficit observed in the children with CF. Third, the group of children with CF was selected to have only mild pulmonary symptoms; therefore, it can be speculated that in a more representative group of children with CF, the growth deficit over 3 y would have been larger than the one observed in the present study. The agreement between the results of the longitudinal analyses obtained with the 3 methods of body-composition assessment further supports the conclusions of this study. CF genotype group was not associated with body-composition changes, in contrast with the changes in pulmonary function observed in some studies (36). A larger sample in each genotype group as well as inclusion of subjects without pancreatic insufficiency may, however, be necessary to detect such differences.

In conclusion, the results of this longitudinal study indicate that children with CF do not grow at an optimal rate on the basis of the growth rates observed in the group of healthy control subjects, despite comprehensive care that includes nutrition education. The boys with CF tended to gain less FFM and less FM than did control boys, and less FM than did girls with CF. Therefore, cross-sectional assessments of children with CF need to be interpreted with caution and optimal nutritional and overall clinical care can only be evaluated after careful longitudinal observations of appropriate growth over several years. It is recommended that better surveillance of growth and body composition should be conducted in children with CF by using standard protocols, accurate equipment, and well-trained observers, to allow earlier recognition and treatment of suboptimal growth.


   ACKNOWLEDGMENTS
 
We thank the children and their families who took part in the study as well as the staff of the Cystic Fibrosis Center and General Clinical Research Center for their assistance.


   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Corey M, McLaughlin FJ, Williams M, Levison H. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol 1988;41:583–91.[Medline]
  2. Kerem E, Reisman J, Corey M, Canny GJ, Levison H. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992;326: 1187–91.[Abstract]
  3. Nir M, Lanng S, Johansen HK, Koch C. Long-term survival and nutritional data in patients with cystic fibrosis treated in a Danish center. Thorax 1996;51:1023–7.[Abstract/Free Full Text]
  4. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation patient registry annual data report. Bethesda, MD: Cystic Fibrosis Foundation, 1996.
  5. Rosenfeld M, Davis R, FitzSimmons S, Pepe M, Ramsey B. Gender gap in cystic fibrosis mortality. Am J Epidemiol 1997;145:794–803.[Abstract/Free Full Text]
  6. Ionescu AA, Chatham K, Davies CA, Nixon LS, Enright S, Shale DJ. Inspiratory muscle function and body composition in cystic fibrosis. Am J Respir Crit Care Med 1998;158:1271–6.[Abstract/Free Full Text]
  7. Lai HC, Corey M, FitzSimmons S, Kosorok MR, Farrell PM. Comparison of growth status of patient with cystic fibrosis between the United States and Canada. Am J Clin Nutr 1999;69:531–8.[Abstract/Free Full Text]
  8. Newby MJ, Keim NL, Brown DL. Body composition of adult cystic fibrosis patients and control subjects as determined by densitometry, bioelectrical impedance, total-body electrical conductivity, skinfold measurements, and deuterium oxide dilution. Am J Clin Nutr 1990; 52:209–13.[Abstract/Free Full Text]
  9. Lands LC, Gordon C, Bar-Or O, et al. Comparison of three techniques for body composition analysis in cystic fibrosis. J Appl Physiol 1993;75:162–6.[Abstract/Free Full Text]
  10. Tomezsko JL, Scanlin TF, Stallings VA. Body composition of children with cystic fibrosis with mild clinical manifestations compared with normal children. Am J Clin Nutr 1994;59:123–8.[Abstract/Free Full Text]
  11. Kerem B, Rommens JM, Buchanan JA, et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989;245:1073–80.[Abstract/Free Full Text]
  12. Cameron N. The methods of auxologic anthropometry. In: Falkner F, Tanner J, eds. Human growth. Vol 3. New York: Plenum Press, 1986:3–43.
  13. Tanner JM. Growth in adolescence. Oxford, United Kingdom: Blackwell, 1963.
  14. Frisancho AR. New norms of upper limb fat and muscle areas for assessment of nutritional status. Am J Clin Nutr 1981;34:2540–5.[Abstract/Free Full Text]
  15. Durnin JVGA, Rahaman MM. The assessment of the amount of fat in the human body from measurements of skinfold thickness. Br J Nutr 1967;21:681–9.[Medline]
  16. Brook CGD. Determination of body composition of children from skinfold measurements. Arch Dis Child 1971;46:182–4.
  17. Schoeller DA, van Santen E, Peterson DW, et al. Total body water measurement in humans with 18O and 2H labeled water. Am J Clin Nutr 1980;33:2686–93.[Abstract/Free Full Text]
  18. Tomezsko JL, Stallings VA, Kawchak DA, Goin JE, Diamond G, Scanlin TF. Energy expenditure and genotype of children with cystic fibrosis. Pediatr Res 1994;35:451–60.[Medline]
  19. Boileau RA, Lohman TG, Slaughter MH, Ball TE, Going SB, Hendrix MK. Hydration of the fat-free body in children during maturation. Hum Biol 1984;56:651–66.[Medline]
  20. Lukaski HC. Methods for assessment of human body composition: traditional and new. Am J Clin Nutr 1987;46:537–56.[Abstract/Free Full Text]
  21. Van Loan MD. Assessment of fat-free mass in teen-agers: use of TOBEC methodology. Am J Clin Nutr 1990;52:586–90.[Abstract/Free Full Text]
  22. Hamill PV, Drizd TA, Johnson CL, Reed RB, Roche AF, Moore WM. Physical growth: National Center for Health Statistics percentiles. Am J Clin Nutr 1979;32:607–29.[Abstract/Free Full Text]
  23. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963–74.[Medline]
  24. Shepherd RW, Thomas BJ, Bennett D, Cooksley WG, Ward LC. Changes in body composition and muscle protein degradation during nutritional supplementation in nutritionally growth-retarded children with cystic fibrosis. J Pediatr Gastroenterol Nutr 1983;2:439–46.[Medline]
  25. Greer R, Shepherd R, Cleghorn G, Bowling FG, Holt T. Evaluation of growth and changes in body composition following neonatal diagnosis of cystic fibrosis. J Pediatr Gastroenterol Nutr 1991;13:52–8.[Medline]
  26. Spicher V, Roulet M, Schaffner C, Schutz Y. Bio-electrical impedance analysis for estimation of fat-free mass and muscle mass in cystic fibrosis patients. Eur J Pediatr 1993;152:222–5.[Medline]
  27. Rochat T, Slosman DO, Pichard C, Belli DC. Body composition analysis by dual-energy x-ray absorptiometry in adults with cystic fibrosis. Chest 1994;106:800–5.[Abstract/Free Full Text]
  28. Allen JR, Humphries IR, McCauley JC, et al. Assessment of body composition of children with cystic fibrosis (CF). Appl Radiat Isot 1998;49:591–2.[Medline]
  29. Farrell PM, Kosorok MR, Laxova A, et al. Nutritional benefits of neonatal screening for cystic fibrosis. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. N Engl J Med 1997;337:963–9.[Abstract/Free Full Text]
  30. Karlberg J, Kjellmer I, Kristiansson B. Linear growth in children with cystic fibrosis. I. Birth to 8 years of age. Acta Paediatr Scand 1991;80:508–14.[Medline]
  31. Henderson RC, Madsen CD. Bone density in children and adolescents with cystic fibrosis. J Pediatr 1996;128:28–34.[Medline]
  32. Bhudhikanok GS, Wang MC, Marcus R, Harkins A, Moss RB, Bachrach LK. Bone acquisition and loss in children and adults with cystic fibrosis: a longitudinal study. J Pediatr 1998;133:18–27.[Medline]
  33. Johnston JL, Leong MS, Checkland EG, Zuberbuhler PC, Conger PR, Quinney HA. Body fat assessed from body density and estimated from skinfold thickness in normal children and children with cystic fibrosis. Am J Clin Nutr 1988;48:1362–6.[Abstract/Free Full Text]
  34. Zemel BS, Kawchak DA, Cnaan A, Zhao H, Scanlin TF, Stallings VA. Prospective evaluation of resting energy expenditure, nutritional status, pulmonary function, and genotype in children with cystic fibrosis. Pediatr Res 1996;40:578–86.[Medline]
  35. Kawchak DA, Zhao H, Scanlin TF, Tomezsko JL, Cnaan A, Stallings VA. Longitudinal, prospective analysis of dietary intake in children with cystic fibrosis. J Pediatr 1996;129:119–29.[Medline]
  36. Corey M, Edwards L, Levison H, Knowles M. Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr 1997;131:809–14.[Medline]
Received for publication July 6, 1999. Accepted for publication January 13, 2000.




This article has been cited by other articles:


Home page
 Am. J. Clin. Nutr.Home page
J. Trabulsi, R. F Ittenbach, J. I Schall, I. E Olsen, M. Yudkoff, Y. Daikhin, B. S Zemel, and V. A Stallings
Evaluation of formulas for calculating total energy requirements of preadolescent children with cystic fibrosis
Am. J. Clinical Nutrition, January 1, 2007; 85(1): 144 - 151.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
J. Trabulsi, J. I Schall, R. F Ittenbach, I. E Olsen, M. Yudkoff, Y. Daikhin, B. S Zemel, and V. A Stallings
Energy balance and the accuracy of reported energy intake in preadolescent children with cystic fibrosis.
Am. J. Clinical Nutrition, September 1, 2006; 84(3): 523 - 530.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
S. J. King, D. J. Topliss, T. Kotsimbos, I. B. Nyulasi, M. Bailey, P. R. Ebeling, and J. W. Wilson
Reduced bone density in cystic fibrosis: {Delta}F508 mutation is an independent risk factor
Eur. Respir. J., January 1, 2005; 25(1): 54 - 61.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
A. B. Sopher, J. C. Thornton, J. Wang, R. N. Pierson Jr, S. B. Heymsfield, and M. Horlick
Measurement of Percentage of Body Fat in 411 Children and Adolescents: A Comparison of Dual-Energy X-Ray Absorptiometry With a Four-Compartment Model
Pediatrics, May 1, 2004; 113(5): 1285 - 1290.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
G Steinkamp and B Wiedemann
Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project
Thorax, July 1, 2002; 57(7): 596 - 601.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stettler, N.
Right arrow Articles by Zemel, B. S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stettler, N.
Right arrow Articles by Zemel, B. S
Agricola
Right arrow Articles by Stettler, N.
Right arrow Articles by Zemel, B. S

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS